Breaking the ‘Bird’s Nest’: How Amplia Therapeutics is Piercing the Shield of Pancreatic Cancer

In the high-stakes arena of oncology, few foes are as formidable as pancreatic cancer. It is a disease defined by its stealth and its stubbornness, often remaining silent until it has reached an advanced stage. For those diagnosed with advanced pancreatic cancer, the prognosis is sobering: a five-year survival rate of less than 3 per cent.

“Patients deserve better treatments, better options,” says Dr. Chris Burns, CEO and Managing Director of Amplia Therapeutics (ASX: ATX). “That’s what we’re working toward.”

A PhD chemist with 25 years in drug discovery, Dr. Burns is no stranger to the long road of clinical validation. He previously led teams that developed an approved drug for blood cancer, and in 2024, he was a co-recipient of the Prime Minister’s Prize for Innovation. Now, he is applying that veteran expertise to dismantle the biological fortress that makes pancreatic tumors so resistant to traditional medicine.

To understand Amplia’s lead asset, narmafotinib (AMP945), one must first understand why standard chemotherapy often fails. Pancreatic tumors don’t just grow; they build a “fibrotic shield”—a dense, scarred layer of tissue that acts as a physical barrier.

“In my mind, I imagine it as a bit like a bird’s nest that sits around the tumor cells,” Dr. Burns explains. “This thick fibrous tissue stops drugs and the immune system from getting in to attack the cancer.”

While most therapies try to “brute force” their way through this barrier, Amplia’s approach is more surgical. Narmafotinib is a small-molecule drug—taken conveniently as a pill—that inhibits a specific enzyme responsible for building this “nest.”

By breaking apart the fibrous tissue, the drug provides a “one-two punch”:

In the world of biotech, data is the only currency that matters. Amplia’s Phase 2a ACCENT trial is currently generating the kind of figures that capture the attention of both clinicians and the FDA.

The trial, which combines narmafotinib with standard-of-care chemotherapy, has reported an interim Objective Response Rate (ORR) of 35 per cent. In clinical terms, this means over a third of patients saw their tumors shrink by more than 30 per cent, with that reduction maintained for at least two months.

“In many cases, we see tumor size shrink by a lot more than 30 per cent,” notes Dr. Burns. This performance has already earned the company FDA Fast Track Designation, a tailwind that accelerates the regulatory process for drugs addressing serious unmet needs.

Perhaps most critically for a patient group already weakened by disease, the drug has proven to be well-tolerated. “We’re not adding a lot of added toxicity or additional burden,” Burns says, highlighting a key competitive advantage in a sector where the “cure” can often feel as punishing as the disease.

Amplia is currently moving through a high-velocity phase of its corporate lifecycle. As the calendar turns toward mid-2026, the company is approaching several “value inflection” points that could fundamentally re-rate its market standing:

“Phase 2 is where the rubber hits the road,” Dr. Burns notes. “It allows us to start talking to partners in the pharmaceutical industry who have experience in pancreatic cancer drug development.”

For investors, Amplia represents a rare combination: a de-risked leadership team with a proven track record of taking drugs to market, and a clinically validated asset targeting a multi-billion dollar “blind spot” in oncology.

Operating with a lean, specialised team, the company is focused on high-impact milestones rather than sprawling overhead. At its current valuation, Amplia sits in the “hot zone”—sufficiently advanced to have proven safety and efficacy, yet early enough to offer significant upside as it enters registration-enabling trials.

“We are driven to push this forward as aggressively as we can,” says Dr. Burns. For the thousands of families affected by pancreatic cancer, and the investors backing the science, the next few months could be transformative.